Technical Analysis for ATRS - Antares Pharma, Inc.

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide. The company's products include Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle; twin-jector EZ II needle free injectors; Medi-Jet auto injectors; Elestrin, an estrogen replacement gel for the treatment of hot flashes; and Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder. The company is also developing OTREXUP, a product for the delivery of methotrexate using Medi-Jet technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis, and psoriasis; and VIBEX QS T, an auto injector for the treatment of testosterone deficiency or replacement therapy. In addition, it is developing Vibex auto injectors; disposable pen injectors; and Nestragel, a contraceptive gel. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; BioSante Pharmaceuticals, Inc.; Meda Pharmaceuticals; Population Council; and Pfizer Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.